文献速递肾移植

儿童肾移植受者中他克莫司变异性模式及其与新生供者特异性抗体形成的关联

Patterns in Tacrolimus Variability and Association with De Novo Donor-Specific Antibody Formation in Pediatric Kidney Transplant Recipients.
PubMed 文献 · Clin J Am Soc Nephrol · 2022-07-26

该研究在单中心儿童肾移植受者中分析他克莫司谷浓度个体内变异性(IPV)的基线模式,并探讨其与C1q结合新生供者特异性抗体(dnDSA)形成的关系。426例患者共31,125个他克莫司浓度显示移植后10个月IPV达30%稳态基线;220例纳入结局分析,51例形成C1q结合dnDSA。高IPV(变异系数>30%)与dnDSA形成风险升高相关(HR 5.35,95%CI 2.45-11.68),最高四分位组(>41%)关联最强(HR 11.81,95%CI 4.76-29.27)。

要点

  • 儿童肾移植受者他克莫司IPV在移植后10个月达30%稳态基线。
  • C1q结合dnDSA形成者IPV中位数38%,非形成者28%(P<0.001)。
  • IPV>30%者dnDSA形成风险HR 5.35(95%CI 2.45-11.68)。

核心结论

  • 高他克莫司个体内变异性与新生供者特异性抗体形成强烈相关。

研究设计与样本

  • 单中心儿童肾移植受者研究,分析2004至2018年接受单纯肾移植且随访至少12个月(随访至2019年)的全部他克莫司浓度以确定基线变异性。
  • 个体内变异性采用6个月移动窗口内所有样本的变异系数(SD/均值×100%)定义。
  • 2010至2018年移植的部分患者亚组有常规新生供者特异性抗体检测数据。
  • 采用Cox比例风险模型,以他克莫司个体内变异性作为时变变量,分析其与移植结局的关联。
  • 主要结局为C1q结合新生供者特异性抗体形成。

主要发现

  • 426例患者共31,125个他克莫司浓度显示,移植后10个月个体内变异性达30%稳态基线。
  • 结局研究纳入220例患者,其中51例形成C1q结合新生供者特异性抗体。
  • 新生供者特异性抗体形成者个体内变异性中位数38%(四分位距28%-48%),非形成者28%(四分位距20%-38%),P<0.001。
  • 高他克莫司个体内变异性(变异系数>30%)者新生供者特异性抗体形成风险HR 5.35(95%CI 2.45-11.68)。
  • 他克莫司个体内变异性最高四分位组(变异系数>41%)与C1q结合新生供者特异性抗体形成关联最强,HR 11.81(95%CI 4.76-29.27)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: High tacrolimus intrapatient variability has been associated with inferior graft outcomes in patients with kidney transplants. We studied baseline patterns of tacrolimus intrapatient variability in pediatric patients with kidney transplants and examined these patterns in relation to C1q-binding de novo donor-specific antibodies. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: All tacrolimus levels in participants who underwent kidney-only transplantation at a single pediatric center from 2004 to 2018 (with at least 12-month follow-up, followed until 2019) were analyzed to determine baseline variability. Intrapatient variability was defined using the coefficient of variation (SD/mean ×100%) of all samples in a 6-month moving window. Routine de novo donor-specific antibody measurements were available for a subgroup of patients transplanted in 2010-2018. Cox proportional hazards models using tacrolimus intrapatient variability as a time-varying variable were used to examine the association between intrapatient variability and graft outcomes. The primary outcome of interest was C1q-binding de novo donor-specific antibody formation. RESULTS: Tacrolimus intrapatient variability developed a steady-state baseline of 30% at 10 months post-transplant in 426 patients with a combined 31,125 tacrolimus levels. Included in the outcomes study were 220 patients, of whom 51 developed C1q-binding de novo donor-specific antibodies. De novo donor-specific antibody formers had higher intrapatient variability, with a median of 38% (interquartile range, 28%-48%) compared with 28% (interquartile range, 20%-38%) for nondonor-specific antibody formers (P<0.001). Patients with high tacrolimus intrapatient variability (coefficient of variation >30%) had higher risk of de novo donor-specific antibody formation (hazard ratio, 5.35; 95% confidence interval, 2.45 to 11.68). Patients in the top quartile of tacrolimus intrapatient variability (coefficient of variation >41%) had the strongest association with C1q-binding de novo donor-specific antibody formation (hazard ratio, 11.81; 95% confidence interval, 4.76 to 29.27). CONCLUSIONS: High tacrolimus intrapatient variability was strongly associated with de novo donor-specific antibody formation.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Piburn KH, Sigurjonsdottir VK, Indridason OS, et al. Patterns in Tacrolimus Variability and Association with De Novo Donor-Specific Antibody Formation in Pediatric Kidney Transplant Recipients. Clin J Am Soc Nephrol. 2022. PMID: 35882506. doi:10.2215/CJN.16421221

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。